We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.
- Authors
Woo, Peter Y. M.; Ho, Joanna W. K.; Ko, Natalie M. W.; Li, Ronald P. T.; Jian, Leo; Chu, Alberto C. H.; Kwan, Marco C. L.; Chan, Yung; Wong, Alain K. S.; Wong, Hoi-Tung; Chan, Kwong-Yau; Kwok, John C. K.
- Abstract
<bold>Asbtract: </bold>BACKGROUND: There are limited neuroprotective treatment options for patients with aneurysmal subarachnoid hemorrhage (SAH). Cerebrolysin, a brain-specific proposed pleiotropic neuroprotective agent, has been suggested to improve global functional outcomes in ischemic stroke. We investigated the efficacy, safety and feasibility of administering Cerebrolysin for SAH patients.<bold>Methods: </bold>This was a prospective, randomized, double-blind, placebo-controlled, single-center, parallel-group pilot study. Fifty patients received either daily Cerebrolysin (30 ml/day) or a placebo (saline) for 14 days (25 patients per study group). The primary endpoint was a favorable Extended Glasgow Outcome Scale (GOSE) of 5 to 8 (moderate disability to good recovery) at six-months. Secondary endpoints included the modified Ranking Scale (mRS), the Montreal Cognitive Assessment (MOCA) score, occurrence of adverse effects and the occurrence of delayed cerebral ischemia (DCI).<bold>Results: </bold>No severe adverse effects or mortality attributable to Cerebrolysin were observed. No significant difference was detected in the proportion of patients with favorable six-month GOSE in either study group (odds ratio (OR): 1.49; 95% confidence interval (CI): 0.43-5.17). Secondary functional outcome measures for favorable six-month recovery i.e. a mRS of 0 to 3 (OR: 3.45; 95% CI 0.79-15.01) were comparable for both groups. Similarly, there was no difference in MOCA neurocognitive performance (p-value: 0.75) and in the incidence of DCI (OR: 0.85 95% CI: 0.28-2.59).<bold>Conclusions: </bold>Use of Cerebrolysin in addition to standard-of-care management of aneurysmal SAH is safe, well tolerated and feasible. However, the neutral results of this trial suggest that it does not improve the six-month global functional performance of patients.<bold>Clinical Trial Registration: </bold>Name of Registry: ClinicalTrials.gov Trial Registration Number: NCT01787123 . Date of Registration: 8th February 2013.
- Subjects
SUBARACHNOID hemorrhage; CLINICAL trial registries; MONTREAL Cognitive Assessment; CEREBRAL ischemia
- Publication
BMC Neurology, 2020, Vol 20, Issue 1, pN.PAG
- ISSN
1471-2377
- Publication type
journal article
- DOI
10.1186/s12883-020-01908-9